Realm Therapeutics PLC Result of AGM (2816H)
June 06 2017 - 5:05AM
UK Regulatory
TIDMRLM
RNS Number : 2816H
Realm Therapeutics PLC
06 June 2017
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Result of 2017 Annual General Meeting
6 June 2017 - Realm Therapeutics plc (AIM: RLM), a clinical
stage biopharmaceutical company focused on leveraging its
proprietary immunomodulatory technology, today announces that all
Resolutions put to shareholders were duly passed at its Annual
General Meeting held earlier today. Proxy figures will be displayed
shortly on the Company's website at www.realmtx.com.
Enquiries:
+44 (0) 20 3727
Realm Therapeutics plc 1000
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser & +44 (0) 20 7496
Broker) 3000
Aubrey Powell / Lauren Kettle
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated drug development programmes, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes its formulations have novel immunomodulatory activity with
potential application for the treatment of diseases in a number of
therapeutic areas, including Dermatology and Ophthalmology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUNRRRBSANRAR
(END) Dow Jones Newswires
June 06, 2017 06:05 ET (10:05 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Realm Thera. (London Stock Exchange): 0 recent articles
More Realm Thera. News Articles